JP2015129764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015129764A5 JP2015129764A5 JP2015038493A JP2015038493A JP2015129764A5 JP 2015129764 A5 JP2015129764 A5 JP 2015129764A5 JP 2015038493 A JP2015038493 A JP 2015038493A JP 2015038493 A JP2015038493 A JP 2015038493A JP 2015129764 A5 JP2015129764 A5 JP 2015129764A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- threshold
- stage
- measured concentration
- likelihood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007423 decrease Effects 0.000 claims 16
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 11
- 208000033626 Renal failure acute Diseases 0.000 claims 11
- 201000011040 acute kidney failure Diseases 0.000 claims 11
- 208000012998 acute renal failure Diseases 0.000 claims 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 210000001124 body fluid Anatomy 0.000 claims 7
- 210000003734 kidney Anatomy 0.000 claims 7
- 238000003556 assay Methods 0.000 claims 6
- 229940109239 creatinine Drugs 0.000 claims 5
- 230000003907 kidney function Effects 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 238000012959 renal replacement therapy Methods 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 102000012607 Thrombomodulin Human genes 0.000 claims 3
- 108010079274 Thrombomodulin Proteins 0.000 claims 3
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 230000002250 progressing effect Effects 0.000 claims 3
- 238000013517 stratification Methods 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24400009P | 2009-09-18 | 2009-09-18 | |
| US24399509P | 2009-09-18 | 2009-09-18 | |
| US61/243,995 | 2009-09-18 | ||
| US61/244,000 | 2009-09-18 | ||
| US25463609P | 2009-10-23 | 2009-10-23 | |
| US61/254,636 | 2009-10-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529920A Division JP2013513086A (ja) | 2009-09-18 | 2010-09-17 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016085091A Division JP6403712B2 (ja) | 2009-09-18 | 2016-04-21 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015129764A JP2015129764A (ja) | 2015-07-16 |
| JP2015129764A5 true JP2015129764A5 (https=) | 2016-01-21 |
Family
ID=43759017
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529920A Pending JP2013513086A (ja) | 2009-09-18 | 2010-09-17 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP2015038493A Pending JP2015129764A (ja) | 2009-09-18 | 2015-02-27 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP2016085091A Expired - Fee Related JP6403712B2 (ja) | 2009-09-18 | 2016-04-21 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529920A Pending JP2013513086A (ja) | 2009-09-18 | 2010-09-17 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016085091A Expired - Fee Related JP6403712B2 (ja) | 2009-09-18 | 2016-04-21 | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130045494A1 (https=) |
| EP (2) | EP2470904A4 (https=) |
| JP (3) | JP2013513086A (https=) |
| CN (2) | CN102576012B (https=) |
| AU (2) | AU2010295512B2 (https=) |
| CA (1) | CA2773905A1 (https=) |
| EA (1) | EA201290106A1 (https=) |
| MX (1) | MX2012003168A (https=) |
| NZ (2) | NZ612673A (https=) |
| WO (1) | WO2011035097A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2748605T (pt) * | 2011-08-26 | 2019-05-03 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| US20160147958A1 (en) * | 2013-07-26 | 2016-05-26 | Koninklijke Philips N.V. | Computerization and visualization of clinical rules and definitions for patient monitoring systems |
| GB201501597D0 (en) * | 2015-01-30 | 2015-03-18 | Randox Lab Ltd | Thrombomodulin |
| JP6232689B2 (ja) | 2015-06-25 | 2017-11-22 | 株式会社国際電気通信基礎技術研究所 | 多器官連関システムを基盤とした予測装置、及び予測プログラム |
| US20190033325A1 (en) * | 2016-01-29 | 2019-01-31 | Advanced Telecommunications Research Institute International | Renal function evaluating device, device for predicting onset of kidney disease complications, and phosphorous ingestion amount estimating device |
| CN114594268A (zh) | 2016-03-29 | 2022-06-07 | 无限生物制药公司 | 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法 |
| EP3466446B1 (en) | 2016-03-29 | 2023-12-27 | Karydo Therapeutix, Inc. | Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| JPH0736019B2 (ja) * | 1989-12-27 | 1995-04-19 | 富士薬品工業株式会社 | 新規な抗ヒトトロンボモジュリンモノクローナル抗体によるヒトトロンボモジュリンおよびその分解産物の定量方法 |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| JP3290988B2 (ja) | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6544761B2 (en) * | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
| CN1495258A (zh) * | 1994-12-13 | 2004-05-12 | 人体基因组科学有限公司 | 金属蛋白酶-4的人组织抑制剂 |
| CN1129666C (zh) * | 1994-12-13 | 2003-12-03 | 人体基因组科学有限公司 | 金属蛋白酶－4的人组织抑制剂 |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| WO2001042438A2 (en) * | 1999-12-13 | 2001-06-14 | Regents Of The University Of Minnesota | Leukolysin/mmp25/mt6-mmp |
| AU2002227365A1 (en) * | 2000-12-07 | 2002-06-18 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
| WO2003006989A1 (fr) * | 2001-07-12 | 2003-01-23 | Kyowa Medex Co., Ltd. | Procede de quantification de lipoproteines denaturees, reactifs pour la quantification de lipoproteines denaturees, procede de detection de maladies du systeme circulatoire et reactifs pour la detection de maladies du systeme circulatoire |
| CN1972703A (zh) * | 2004-03-30 | 2007-05-30 | 丹麦皇家兽医和农业学院 | 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测 |
| US7713693B1 (en) * | 2004-09-01 | 2010-05-11 | University Of Louisiana At Monroe | Human cancer cell specific gene transcript |
| US20060160112A1 (en) * | 2004-12-02 | 2006-07-20 | Erdal Cavusoglu | Tissue inhibitor of metalloproteinase (TIMP) as a marker and predictor of cardiovascular disease and both cardiac and non-cardiac mortality |
| US20090178145A1 (en) * | 2005-05-11 | 2009-07-09 | The Procter & Gamble Company | Methods and targets for identifying compounds for regulating angiogenesis |
| WO2007053610A2 (en) * | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
| JP2007163151A (ja) * | 2005-12-09 | 2007-06-28 | Kitasato Gakuen | 対象生物の生理状態を判定する方法 |
| CN101490273A (zh) * | 2006-05-09 | 2009-07-22 | 南卡罗来纳州医科大学研究发展基金会 | 利用蛋白酶和蛋白酶抑制剂血浆分析检测舒张期心力衰竭 |
| MX2008014155A (es) * | 2006-05-09 | 2009-02-25 | Musc Found For Res Dev | Deteccion de insuficiencia cardiaca diastolica por proteasa y determinacion de perfil plasmatico de inhibidor de proteasa. |
| WO2008084331A2 (en) * | 2006-06-21 | 2008-07-17 | Hopitaux Universitaires De Geneve | Biomarkers for renal disorders |
| US8445222B2 (en) * | 2006-07-11 | 2013-05-21 | Musc Foundation For Research Development | Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling |
| GB0617429D0 (en) * | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| FR2909180B1 (fr) * | 2006-11-29 | 2009-02-20 | Diagnostica Stago Soc Par Acti | Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique. |
-
2010
- 2010-09-17 US US13/395,114 patent/US20130045494A1/en not_active Abandoned
- 2010-09-17 AU AU2010295512A patent/AU2010295512B2/en not_active Ceased
- 2010-09-17 EP EP10817878.1A patent/EP2470904A4/en not_active Withdrawn
- 2010-09-17 NZ NZ612673A patent/NZ612673A/en not_active IP Right Cessation
- 2010-09-17 EA EA201290106A patent/EA201290106A1/ru unknown
- 2010-09-17 CN CN201080043037.2A patent/CN102576012B/zh not_active Expired - Fee Related
- 2010-09-17 EP EP17196557.7A patent/EP3299821A1/en not_active Withdrawn
- 2010-09-17 CA CA2773905A patent/CA2773905A1/en not_active Abandoned
- 2010-09-17 JP JP2012529920A patent/JP2013513086A/ja active Pending
- 2010-09-17 WO PCT/US2010/049234 patent/WO2011035097A1/en not_active Ceased
- 2010-09-17 CN CN201510401130.0A patent/CN105004864B/zh not_active Expired - Fee Related
- 2010-09-17 MX MX2012003168A patent/MX2012003168A/es active IP Right Grant
- 2010-09-17 NZ NZ598741A patent/NZ598741A/xx not_active IP Right Cessation
-
2015
- 2015-02-25 AU AU2015200953A patent/AU2015200953A1/en not_active Abandoned
- 2015-02-27 JP JP2015038493A patent/JP2015129764A/ja active Pending
-
2016
- 2016-04-21 JP JP2016085091A patent/JP6403712B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-18 US US16/251,407 patent/US20190250170A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015129764A5 (https=) | ||
| JP2013503344A5 (https=) | ||
| JP2016505143A5 (https=) | ||
| JP2013519095A5 (https=) | ||
| JP2013501920A5 (https=) | ||
| JP2014529073A5 (https=) | ||
| JP2012517594A5 (https=) | ||
| JP2017533427A5 (https=) | ||
| JP2012517592A5 (https=) | ||
| JP2013510321A5 (https=) | ||
| JP2013539861A5 (https=) | ||
| JP2013513086A5 (https=) | ||
| US12203941B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| Basu et al. | Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children | |
| JP2014521088A5 (https=) | ||
| JP2021039112A5 (https=) | ||
| JP2013510322A5 (https=) | ||
| Jefferies et al. | Early detection of acute kidney injury after pediatric cardiac surgery | |
| JP2013519866A5 (https=) | ||
| Llauger et al. | Renal function and acute heart failure outcome | |
| RU2019106326A (ru) | Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции | |
| Langsford et al. | The association between biomarker profiles, etiology of chronic kidney disease, and mortality | |
| Seijas et al. | Definition and biomarkers of acute renal damage: new perspectives | |
| JP2020504157A5 (https=) | ||
| Minicucci et al. | Critical infarct size to induce ventricular remodeling, cardiac dysfunction and heart failure in rats |